Inovio resumes VGX-3100 HPV cancer program

Inovio Pharmaceuticals Inc. (NASDAQ:INO) gained $0.80 (11%) to $8.19 on Thursday after the company said FDA lifted a clinical hold on its Phase III program of VGX-3100 to treat cervical dysplasia caused by HPV. The company plans to immediately begin a pair of Phase III trials of the candidate.

FDA placed the hold on Inovio’s development program for VGX-3100 last October and requested additional data on the shelf life of the company's redesigned Cellectra electroporation device used to administer the product (see BioCentury Extra, Oct. 24, 2016)...